Literature DB >> 17893973

Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.

Emese Kiss1, Ildikó Seres, Tünde Tarr, Zsolt Kocsis, Gyula Szegedi, György Paragh.   

Abstract

Excessive lipid peroxidation is a major factor of accelerated atherosclerosis, observed in patients with systemic lupus erythematosus (SLE). We aimed at the present study to determine the paraoxonasel (PON1) and arylesterase activities, and lipid-profile in 37 SLE patients and 30 age-/sex-matched controls. Association was analyzed between PON1 activity and SLEDAI, CRP, anti-oxLDL, and antiphospholipid antibody (aPL) levels, steroid dose, and atherothrombotic events. The age of patients was 40.8 +/- 13.9 year, follow-up time 6.7 +/- 6.2 year, SLEDAI 2 (0-15). PON1 and arylesterase activities were measured spectrophotometrically using paraoxon and phenyl acetate as substrates, respectively. Phenotypic distribution of PON1 was determined by dual substrate method. We measured antioxLDL and aPL levels by ELISA, the CRP by automated immunoassay. PON1 activity (121.9 +/- 65.9 U/mL) was reduced significantly (P < 0.001) in SLE as compared to control (188.1 +/- 78.9 U/mL), but arylesterase activity was not different. A negative correlation was found between PON1 activity and age. PON1 activity did not correlate with other measured parameters. Reduced PON1 activity associated with clinical atherothrombotic complications (P < 0.01). High activity BB phenotype was not present in SLE. Lipid parameters (TC, LDL-C, HDL-C, ApoAI, and ApoB) were within normal range in both groups. Results indicated reduced PON1 activity in lupus patients despite long disease duration and low inflammatory activity, and it was evidenced as a risk for atherosclerotic complications. As the arylesterase activity was normal, further examinations are required to find other mechanisms, such as anti-PON1 antibodies, genetic polymorphisms, and difference in distribution of HDL-subfractions or enzyme abnormalities in HDL remodeling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893973     DOI: 10.1196/annals.1422.009

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

Review 1.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

2.  Cholesterol-Independent Suppression of Lymphocyte Activation, Autoimmunity, and Glomerulonephritis by Apolipoprotein A-I in Normocholesterolemic Lupus-Prone Mice.

Authors:  Leland L Black; Roshni Srivastava; Trenton R Schoeb; Ray D Moore; Stephen Barnes; Janusz H Kabarowski
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

3.  Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL.

Authors:  Daniel S Kim; Amber A Burt; David R Crosslin; Peggy D Robertson; Jane E Ranchalis; Edward J Boyko; Deborah A Nickerson; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2012-11-15       Impact factor: 5.922

4.  Dietary cholesterol increases paraoxonase 1 enzyme activity.

Authors:  Daniel S Kim; Amber A Burt; Jane E Ranchalis; Rebecca J Richter; Julieann K Marshall; Karen S Nakayama; Ella R Jarvik; Jason F Eintracht; Elisabeth A Rosenthal; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2012-08-15       Impact factor: 5.922

5.  Oxidative stress in chronic otitis media.

Authors:  Elif Baysal; Nurten Aksoy; Ferit Kara; Seyithan Taysi; Abdullah Taşkın; Hasan Bilinç; Cengiz Cevik; Fatih Celenk; Muzaffer Kanlıkama
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-19       Impact factor: 2.503

6.  Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients.

Authors:  Fazile Hatipoglu Erdem; Saliha Karatay; Kadir Yildirim; Ahmet Kiziltunc
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

7.  Correlation of Paraoxonase Status with Disease Activity Score and Systemic Inflammation in Rheumatoid Arthritic Patients.

Authors:  Usha Dudeja Bindal; Rahul Saxena; Merajul Haque Siddiqui; Dilutpal Sharma
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 8.  G2A and LPC: regulatory functions in immunity.

Authors:  Janusz H Kabarowski
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-19       Impact factor: 3.072

9.  Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.

Authors:  Chunyu Liu; Franak Batliwalla; Wentian Li; Annette Lee; Ronenn Roubenoff; Evan Beckman; Houman Khalili; Aarti Damle; Marlena Kern; Richard Furie; Josée Dupuis; Robert M Plenge; Marieke J H Coenen; Timothy W Behrens; John P Carulli; Peter K Gregersen
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

10.  Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Jennifer Grossman; Brian Skaggs; John Fitzgerald; Lori Sahakian; Nagesh Ragavendra; Christina Charles-Schoeman; Karol Watson; Weng Kee Wong; Elizabeth Volkmann; Weiling Chen; Alan Gorn; George Karpouzas; Michael Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheum       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.